The results of a study presented today at the Annual European Congress of Rheumatology 2017 have shown that the combined use of two measurements to accurately predict the risk of relapse in patients with rheumatoid arthritis (RA) allows successful dose reduction (tapering) of their disease modifying anti-rheumatic drugs (DMARDs). This in turn increases the cost-effectiveness of each DMARD treatment.

This post comes from the RSS feed of EurekaAlert, you can find more here!

Written by admin